Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC,is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource® designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Agios Pharmaceuticals, Inc.

Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Acute Myeloid Leukemia

Release Date: March 30, 2018
Expiration Date: March 30, 2019
Media: Internet - based


Activity Overview

This online activity is designed to update physicians on data presented at a major oncology meeting, held in Atlanta, GA, in December 2017, to facilitate critical assessment and, when appropriate, clinical integration of new evidence. The activity reviews 3 abstracts selected by program faculty, Amir T. Fathi, MD, MSc, as the most compelling and clinically relevant from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care. Interactive questions are interspersed throughout the activity to encourage engagement, learning, and self-assessment.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Agios Pharmaceuticals, Inc.

CME Activity Table of Contents

  • Module 1: Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia
  • Module2: The Use of Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
  • Module2: Analysis of the Safety and Efficacy of Enasidenib Monotherapy in Older Patients with Previously Untreated Mutant-IDH2 (mIDH2) Acute Myeloid Leukemia (AML)

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists who treat patients with acute myeloid leukemia (AML). Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with AML are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Detail the design, efficacy, and safety endpoints of ongoing and recently completed clinical trials in patients with AML
  • Explain recent clinical trial results regarding novel compounds and strategies for patients with AML
  • Place presented clinical trial evidence into the context of evolving treatment paradigms and strategies in the management of patients with AML

Faculty, Staff, and Planners' Disclosures


Amir T. Fathi, MD, MSc
Assistant Professor of Medicine
Harvard Medical School
Director, Leukemia Program
Massachusetts General Hospital
Boston, MA

Disclosure:Consultant: Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc., Vaniam Group LLC, AbbVie, Alexion; Research Support: Kite, Regeneron, Acerta; Consultant/Research Support: Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Filter By